SCDM Releases Trends Impacting Clinical Data Management
The Society for Clinical Data Management, SCDM, has released its latest Reflection Paper, “The Evolution of Clinical Data Management to Data Science.” Patrick Nadolny, Chair of the SCDM Innovation Committee and Global Head of Clinical Data Management and Programming at Allergan noted the goal of the paper is to provide a “forward-looking and pragmatic view on why and how emerging study designs, regulations, and technology innovations are reshaping the role and profile of clinical data management. ”
Highlights include: [Link to paper here]
- The impact of the rising complexity of clinical research approaches such as adaptive study design and decentralized clinical trials
- What a continually shifting regulatory environment means for data quality and clinical data management practices, including definitions of data quality and riskâbased clinical data management.
- How new technologies such as Artificial Intelligence (AI) and wearable are transforming clinical trials leading to the reduction of electronic data capture (EDC) centricity moving forward
- Career considerations for clinical data managers – among them how the role of the clinical data manager is changing, why clinical data management is at the heart of riskâbased study execution, and new skillsets necessary for managing the evolution of clinical data.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
